Skip to main content

News

Bristol-Myers stock is falling because the Celgene merger may not make sense

By Barron's  
   May 21, 2019

A stormy honeymoon could be in the offing following the biggest pharmaceutical acquisition in history, according to one analyst. Pharmaceutical behemoth Bristol-Myers Squibb is preparing for the purchase of Celgene, a major biotech company, for a reported $74 billion.

Full story


Get the latest on healthcare leadership in your inbox.